Background: Bipolar disorder co-occurs with a number of disorders with externalizing features. The aim of this study is to determine whether Bipolar I (BPI) subjects with comorbid externalizing disorders and a subgroup with externalizing symptoms prior to age 15 have different clinical features than those without externalizing disorders and whether these could be attributed to specific genetic variations. Methods: A large cohort (N¼ 2505) of Bipolar I subjects was analyzed. Course of illness parameters were compared between an Externalizing Group, an Early-Onset Subgroup and a Non-Externalizing Group in the Discovery sample (N ¼1268). Findings were validated using an independent set of 1237 BPI subjects (Validation sample). Genetic analyses were carried out. Results: Subjects in the Externalizing Group (and Early-Onset Subgroup) tended to have a more severe clinical course, even in areas specifically related to mood disorder such as cycling frequency and rapid mood switching. Regression analysis showed that the differences are not completely explainable by substance use. Genetic analyses identified nominally associated SNPs; calcium channel genes were not enriched in the gene variants identified. Limitations: Validation in independent samples is needed to confirm the genetic findings in the present study. Conclusions: Our findings support the presence of an externalizing disorder subphenotype within BPI with greater severity of mood disorder and possible specific genetic features.
Introduction
Bipolar disorder (BP) includes distinct episodes with altered mood, activity, and thought patterns. The mean age at onset for Bipolar Disorder Type I (BPI) is 18.4 years and the lifetime prevalence is 0.6% (Merikangas et al., 2011) . BP may occur in conjunction with a number of other disorders such as substance use and anxiety disorders (Merikangas et al., 2011) . Substance use has been shown to be highly prevalent in BP patients (Merikangas et al., 2011; Regier et al., 1990) . Prior studies have identified more severe outcomes among BP patients with co-occurring substance use disorders (Cardoso et al., 2008; Elizabeth Sublette et al., 2009; Frye and Salloum, 2006; Grunebaum et al., 2006) . The presence of substance abuse also makes it more difficult to treat BP (Swann, 2010) . The disorder has a substantial genetic component. Monozygotic twin concordance rates range from 45% to 70% and sibling recurrence risk ranges from 5% to 10% (Craddock and Forty, 2006) . Genome-Wide Association Studies (GWAS) have identified 10 common variants with modest effects (Chen et al., 2013; Ferreira et al., 2008; Seifuddin et al., 2012; Sklar, 2013; Sklar et al., 2011; Smith et al., 2009 Smith et al., , 2011 , and analyses using the entire set of variants tested with common GWAS platforms suggest that many additional vulnerability genes remain to be identified as larger samples become available (Cross-Disorder Group of the Psychiatric Genomics Consortium et al., 2013; Lee et al., 2011) . Many course of illness parameters have also been shown to be heritable (Potash et al., 2007) . The aim of this study is to determine whether a subphenotype of BPI subjects can be defined based on the presence of externalizing disorders, and whether these subjects are clinically and/or genetically different from those who did not have externalizing disorders. We were particularly interested in whether the characteristics of the mood disorder itself (apart from externalizing symptoms) differentiated the subgroups. Two sets of BPI subj ects ascertained by the National Institute of Mental Health (NIMH) Bipolar Disorder Genetics Initiative and evaluated with the Diagn ostic Instrument for Genetic Studies (Nurnberger et al., 1994) were Contents lists available at ScienceDirect journal homepage: www.elsevier.com/locate/jad
Validation sample
The validation sample consisted of 1237 unrelated EA BPI subjects from the same study. Based on the above mentioned criteria, these subjects were also divided into 1) the Non-Externalizing Group-436 subjects; 2) the Externalizing Group-801 subjects and 3) the EarlyOnset Subgroup-307 subjects (Table 1) . Of note, about 20% of subjects in this sample came from multiplex families.
Clinical assessment
All subjects were interviewed with the Diagnostic Interview for Genetic Studies (DIGS) (Nurnberger et al., 1994) , a diagnostic instrument developed for determining mood disorders and related conditions and shown to have excellent test-retest reliability. Final diagnoses were made by two independent clinicians incorporating all available information using a best-estimate procedure.
2.2. Genome-wide association analyses 2.2.1. Genotyping and quality control of data available on dbGaP
Genotyping was carried out at The Broad Institute Center for Genotyping and Analysis. PicoGreen fluorometry was used to check DNA quantity, and sample quality was initially assessed by genotyping a 24-single nucleotide polymorphism (SNP) panel on the Sequenom iPLEX platform containing a sex determining assay. Samples were plated at 50 ng/μl in 96 well plates at the Rutgers University Cell and DNA Repository. The Centre d'Etude du Polymorphisme Human (CEPH; http://www.cephb.fr/en/cephdb/) sample NA12144 was placed on each production plate at the Broad Institute. Genotyping was carried out separately for the EA and AA samples using the Affymetrix GenomeWide Human SNP Array 6.0. Allele calling was performed using the BirdSeed algorithm Affymetrix Power Tools version apt-1.8.6 and cluster models ('priors') file. Concordance between genotypes from the array and those from the initial quality control (QC) panel was evaluated to confirm sample ID. BPI EA Discovery and Validation samples were pooled together for the GWAS.
Samples were not used in the analysis if they had a low call rate (o98.5%) or incompatibility between reported gender and genetically determined gender. Pairwise identity-by-descent estimation was used to check for unexpected familial relationships in PLINK v1.07 (Purcell et al., 2007 Smith et al. (2009 Smith et al. ( , 2011 .
Statistical analyses
2.3.1. Clinical parameter analyses Statistical analyses were performed between the Non-Externalizing Group and the Externalizing Group of BPI subjects (including both early-onset and later-onset subjects), and between the NonExternalizing Group and the Early-Onset Subgroup. Categorical variables were analyzed using the Pearson chi-square test (two-sided) and continuous variables were analyzed using an independent samples ttest (two-sided). Levene's Test for Equality of Variances was performed to check the equality of variances assumption. All statistical analyses were performed in SPSS Statistics.
Genetic analyses
All genetic analyses were conducted using PLINK v1.07. The analyses involved testing the association of each SNP coded additively with externalizing and early-onset status, with subject sex included as a covariate in the logistic model employed.
Results

Subject distribution in the Non-Externalizing and Externalizing Groups
1268 BPI subjects (951 EA, 317 AA) were included in the Discovery phase of the analysis and the findings were validated using 1237 BPI subjects in the Validation sample (Table 1 ). The distribution of BPI subjects among the Non-Externalizing and Externalizing Groups, and the Early-Onset Subgroup was similar for the two samples.
Prevalence of externalizing disorders
We then examined the distribution of externalizing disorders in the Externalizing Group of BPI subjects in the two studies (Table 2) . A majority of subjects had alcohol abuse/dependence and/or drug abuse/dependence. A higher proportion (P o0.05) of Discovery sample subjects had drug abuse/dependence and ASPD compared to Validation sample subjects. Conversely, a higher proportion (P o0.05) of Validation sample subjects had ADHD compared to Discovery sample subjects, but this may be related to assessment methodology (see Section 4). Further information on the breakdown of substance use disorders in the sample cohort can be found in Table S1 .
Clinical characteristics
A number of clinical parameters were found to be significantly (Po0.05) different when comparing the Externalizing Group to the Non-Externalizing Group of BPI subjects in the Discovery sample (Tables 3 and 4) . Subjects in the Externalizing Group were more likely to be male (χ 2 ¼ 9.012, df¼1, P¼0.003), to be disabled (χ 2 ¼6.932, df¼1, P¼ 0.008) and to have fewer years of schooling (t¼6.694, df¼1217, Po0.001). They had an earlier age at onset of BPI (t¼7.250, df¼ 776.393, Po0.001) (including earlier onset ages for both depression (t¼5.533, df¼796.274, Po0.001) and mania (t¼5.807, df¼ 837.128, Po0.001)), a higher number of depressive (χ 2 ¼20.902, df¼1, Po0.001) and manic episodes (χ 2 ¼12.613, df¼ 1, Po0.001, excluding episodes judged to be secondary to substance use) and a higher frequency of episodes (χ 2 ¼9.763, df¼ 1, P¼0.002; χ 2 ¼4.179, df¼ 1, P¼0.041). The subjects in the Externalizing Group had an increased frequency of incidents of (non-suicidal) self-harm (χ 2 ¼25.797, df¼ 1, Po0.001) and more suicide attempts (t¼ À2.680, df¼478.609, P¼0.008). They were rated as more impaired on the interepisode Global Assessment Scale (GAS) (t¼ 3.771, df¼474, Po0.001) and were more likely to report a history of rapid switching (χ 2 ¼ 21.696, df¼ 1, Po0.001) and rapid cycling (χ 2 ¼25.516, df¼1, Po0.001). We have investigated the effect of ethnicity in externalizing disorders and we find similar results for EA and AA except for disability, frequency of depressive episodes, number and frequency of manic episodes, and age of first tobacco use in case of AA (Tables S2,  S3 , S4 and S5). The findings in BPI subjects in the overall Discovery sample (Tables 3 and 4) were replicated in BPI subjects in the Validation sample (Tables S6 and S7) . Examination of the clinical variables in the Early-Onset Subgroup shows the same pattern as in the Externalizing Group as a whole, but in general the differences are greater. Non-suicidal self-harm was seen in 30.2% of early-onset subjects as compared to 10.0% of nonexternalizing subjects (and 26.0% of externalizing subjects as a whole). Rapid switching was seen in 70.6% of early-onset subjects as compared to 48.6% of non-externalizing subjects (and 62.8% of externalizing subjects). Although they are younger, 56.7% of early-onset externalizing subjects have had 48 non-substance-related depressive episodes in their lifetime compared with 35.5% of non-externalizing subjects (and 49.5% of externalizing subjects); 55.1% have had 44 nonsubstance-related manic episodes in their lifetime compared with 42.8% of non-externalizing subjects (and 53.5% of externalizing subjects). They have an earlier age of onset of bipolar disorder by more than 5 years (at 16.0 years compared to 20.4 years) and these ages are similar to the ages of first depressive episode; age of first mania is also advanced by more than 5 years (21.3 years compared to 26.6 years). Number of suicide attempts is greater (3.6 vs. 2.6) and age of first attempt is 44 years earlier (20.3 years vs. 24.5 years). Patterns are very similar in the Validation sample.
To determine whether the differences in the clinical parameters between subjects in the Non-Externalizing and Externalizing Groups can be accounted for by substance use disorders, separate linear regression analyses were performed using frequency of clean depressive episodes/clean manic episodes as the dependent variable, and externalizing disorder status, presence of alcohol abuse/dependence, presence of drug abuse/dependence, ethnicity, presence/absence of first degree relatives with BPI and cohort (years of ascertainment) as independent variables controlling for age and gender in the Discovery sample. The frequency of depressive episodes was found to be a function of externalizing disorder status (standardized β¼0.119, P¼0.021), but was not completely explained by the presence of alcohol abuse/dependence (P40.05) or drug abuse/dependence (P40.05). The frequency of manic episodes was not found to be a function of externalizing disorder status (P40.05), the presence of alcohol abuse/dependence (P40.05) or the presence of drug abuse/ dependence (P40.05), but appeared to be related to cohort (Po0.05). This may be related to the preponderance of multiplex families in the earlier cohorts. We further examined the effect of externalizing disorder status controlling for alcohol abuse/dependence in one analysis and drug abuse/dependence in a separate analysis on age at onset of BPI, one of the clinical parameters observed to be significantly different between the Non-Externalizing and Externalizing Groups. A significant (Po0.05) effect of externalizing disorder status was still observed even when controlling for alcohol and drug use disorders in the two analyses (data not shown). This suggests that other externalizing disorders such as ASPD , pathological gambling (Kim et al., 2006) , ADHD and CD (Masi et al., 2008) may explain a substantial part of the differences seen in the clinical parameters between the Externalizing and Non-Externalizing Groups.
Genetic association analyses
Two GWAS analyses were performed comparing: 1) 784 subjects in the Non-Externalizing Group vs. 1280 subjects in the Externalizing Group; 2) 784 subjects in the Non-Externalizing Group vs. 502 subjects in the Early-Onset Subgroup. QC was performed on all subjects and all SNPs, as summarized above. Although no SNP reached genome-wide significance (Po 5 Â 10 À 8 ) from the two analyses, a number of SNPs were found to be associated at a P-value of 10 À 5 or lower. Details of 20 SNPs with the strongest association signals from each of the two analyses are shown in Table 5 . Since gene variants associated with bipolar disorder have been reported to be enriched for calcium channel genes, we examined that pathway (Cross-Disorder Group of the Psychiatric Genomics Consortium, 2013; Sklar et al., 2011) but saw no evidence for enrichment of calcium channel genes in either analysis. We also performed GWAS analyses comparing each of the three groups with the control group, but did not identify any a According to the DSM-IV, a clean depressive episode is a depressive episode without prior physical illness, drug or alcohol abuse, organic precipitants, or bereavement. b According to the DSM-IV, a clean manic episode is a manic episode without prior physical illness, drug or alcohol abuse, or organic precipitants.
genome-wide significant SNPs in any of these comparisons (data not shown).
Discussion
The purpose of this study was to determine clinical and genetic differences between BPI subjects who had externalizing disorders and those who did not have externalizing disorders. We found that a majority of Discovery and Validation sample BPI subjects had externalizing disorders. We believe that this is the largest cohort of BPI subjects (total N¼2505) analyzed for factors associated with externalizing symptomatology. Two factors: internalizing and externalizing, appear to substantially account for psychiatric comorbidity among BPI subjects (Monahan et al., in press) .
A significant difference in a majority of clinical parameters was found when we compared subjects in the Non-Externalizing and Externalizing Groups as well as subjects in the Non-Externalizing Group and the Early-Onset Subgroup (Tables 3 and 4, online Tables S6 and S7) .
A possible explanation for the differences seen between these groups is the high proportion of subjects with alcohol abuse/dependence and/or drug abuse/dependence (Table 2 ). However, our regression studies show that the differences in clinical parameters are not completely explained by the presence or absence of substance use disorders.
The most remarkable result of this study was the increased severity and frequency of mood disorder symptoms and episodes in the Externalizing Group and particularly in the Early-Onset Externalizing Subgroup. In every parameter tested, subjects with externalizing disorders show evidence of greater symptomatology, earlier onset, and more impairment. This is true even when care is taken to exclude the direct effects of substances (e.g. the exclusion of substance-related depressive or manic episodes). In general the chronology suggests that substance use precedes episodes of major mood disorder but it is not clear whether minor mood problems may precede substance use or abuse. In any case, the divisions highlighted in this report appear to be clinically salient.
We noted a higher proportion of subjects in the Validation sample with ADHD compared to the Discovery sample. A section for adult ADHD was included in DIGS 4.0 used for later cohorts but the earlier versions had only a retrospective report of childhood ADHD. Inclusion of the adult ADHD section may be expected to have increased the frequency of ADHD reports (including retrospective childhood ADHD). It is not clear to us how to explain the decrease in ASPD diagnoses and drug abuse/dependence diagnoses in the Validation Sample compared to the Discovery sample. Site effects cannot be ruled out (as the four original sites contributed to a larger proportion of the Discovery sample in comparison to the Validation sample), and such effects have been demonstrated in other studies of bipolar subphenotypes (Saunders et al., 2008) . However it is reassuring to note the similarity of the proportions of externalizing and early-onset subjects in the two samples, as well as the very similar results with respect to clinical variables (Tables 3 and 4, Tables S6 and S7) . Although no SNP reached genome-wide significance (Po5 Â 10 À 8 ) in the two GWAS analyses, a number of potential candidate SNPs were found to be nominally associated (Po10 À 5 ) ( Table 5) . Two intronic SNPs (rs9359856 and rs6934804) and one coding SNP (rs2273238) were identified in the ANKRD6 (ankyrin repeat domain 6) gene on chromosome 6. Also known as Diversin, the gene has been shown to be an essential component of the Wnt-signaling pathway, controlling fusion of heart precursors and gastrulation movements in zebrafish embryogenesis (Moeller et al., 2006; Schwarz-Romond et al., 2002) . It has been shown to be prominently expressed in the developing mouse brain suggesting a role during brain development and variants in the gene have been associated with muscle performance and habitual physical activity (Tissir et al., 2002; Van Deveire et al., 2012) . A SNP in a gene in the same family (ANKRD26) was also noted in this short list. Variants in other identified genes have been associated with fasting glucose-related traits (GLIS3, TMEM195 and ZMAT4) (Dupuis et al., 2010; Meigs et al., 2007 ) and Alzheimer's disease (MTHFD1L) (Naj et al., 2010) . Cerebral glucose metabolic rates are known to be altered in mood disorders (Baxter et al., 1985; Drevets et al., 1997) . SNPs in or near ST6GALNAC3, associated with carbohydrate metabolism, are seen three times in this list of 40. Thus, a number of SNPs associated with other diseases/complex traits may play a role in predisposition to externalizing disorders in the presence of bipolar illness. There is no evidence of an enrichment of calcium channel genes, suggesting that this pathway is not likely to explain the difference between externalizing and non-externalizing subtypes of BPI disorder.
The present study includes 2505 unrelated BPI subjects in two samples with clinical and genetic data. Subjects from two different ethnic populations (EA and AA) were analyzed for clinical parameters. However, this is a modest sample size for GWAS analyses and possible significant associations are likely to have been missed. Validation at genome-wide significance levels would be needed to confirm the suggestive associations identified in the present study.
Conclusion
In sum, we have demonstrated that BPI subjects with externalizing disorders tend to have a poorer clinical outcome then those without externalizing disorders; this is particularly true of those subjects with early onset of conduct disorder symptoms. Although no SNP reached genome-wide significance in the GWAS analyses, it does seem important to us that calcium channel genes do not appear to explain the genetic variance between Externalizing and Non-Externalizing Groups of BPI subjects. The clinical results in particular suggest the presence of an externalizing disorder subphenotype within BPI warranting further investigation.
